AF
BCAX

Avanza Fonder’s Bicara Therapeutics BCAX Stock Holding History

Avanza Fonder’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,039
Closed -$84.8K – 512
2025
Q4 		$84.8K Sell
5,039
-4,332
-46% -$74K ﹤0.01% 481
2025
Q3 		$148K Buy
9,371
+2,804
+43% +$31.4K ﹤0.01% 400
2025
Q2 		$61K Sell
6,567
-86
-1% -$1.02K ﹤0.01% 423
2025
Q1 		$88.2K Buy
+6,653
New +$88.3K ﹤0.01% 442

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Avanza Fonder's BCAX Position: Q1 2026 in Review

Avanza Fonder sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 5,039 shares — an estimated $84.8K sold.

Avanza Fonder first reported a position in BCAX in Q1 2025 and held it in 4 quarters. The position peaked at $148K in Q3 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Avanza Fonder reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Avanza Fonder sold 5,039 Bicara Therapeutics shares in Q1 2026, an estimated $84.8K.
  • Avanza Fonder first reported a position in Bicara Therapeutics in Q1 2025 and held it in 4 quarters.
  • Avanza Fonder's Bicara Therapeutics position peaked at $148K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.